Compare · IMDX vs LMDX
IMDX vs LMDX
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and LumiraDx Limited (LMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and LMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LMDX is the larger of the two at $2.23B, about 24.4x IMDX ($91.3M).
- IMDX has hit the wire 3 times in the past 4 weeks while LMDX has been quiet.
- LMDX has more recent analyst coverage (4 ratings vs 0 for IMDX).
- Company
- Insight Molecular Diagnostics Inc.
- LumiraDx Limited
- Price
- -
- -
- Market cap
- $91.3M
- $2.23B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 0
- Recent ratings
- 0
- 4
Latest IMDX
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
- iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
- Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
- SEC Form S-8 filed by Insight Molecular Diagnostics Inc.
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points